## Correction to "Long-Acting β2-Adrenoceptor Agonists Enhance Glucocorticoid Receptor (GR)–Mediated Transcription by Gene-Specific Mechanisms Rather Than Generic Effects via GR"

In the above article [Rider CF, Altonsy MO, Mostafa MM, Shah SV, Sasse S, Manson ML, Yan D, Kärrman-Mårdh C, Miller-Larsson A, Gerber AN, Giembycz MA, and Newton R (2018), *Mol Pharmacol*, **94:** 1031-1046; DOI: https://doi.org/10.1124/mol.118.112755], funding from the National Institutes of Health National Heart, Lung, and Blood Institute was not cited. The funding footnote should read:

This work was supported by research contracts with AstraZeneca (R.N., M.A.G.); Canadian Institutes of Health Research [Grant MOP 125918] (R.N.); Alberta Innovates—Health Solutions Senior Scholar award (R.N.) and studentship (C.F.R.); Lung Association—Alberta & NWT studentship (C.F.R., M.M.M.); and the National Institutes of Health National Heart, Lung, and Blood Institute [Grant HL109557] (S.S., A.N.G.).

The authors apologize for any inconvenience caused by this error.

Downloaded from molpharm.aspetjournals.org at ASPET Journals on April 19, 2024